Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Shounak Majumder

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7687-049X; OpenAlex author ID A5016623207, A5070432554, A5135247784, A5137397268; NIH RePORTER profile ID 15726305. Sources: ClinicalTrials.gov.

Their work

Papers
39 (first author 1, last author 15)
Trials
2 (principal investigator on 2)
Grants
1
Labs led
1
Collaborators
109
Papers, trials and grants by year

2000: 1 trial · 2001: none · 2002: none · 2003: none · 2004: none · 2005: none · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: none · 2012: 2 papers · 2013: 1 paper · 2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: 1 trial · 2019: 2 papers · 2020: 4 papers · 2021: 4 papers · 2022: 5 papers · 2023: 3 papers · 2024: 3 papers · 2025: 5 papers · 2026: 9 papers, 1 grant

Papers 39

  1. Enhanced Molecular Staging of Pancreatic Cancer Using Methylated DNA Markers in Peritoneal Lavage Fluid. Last author DOI 10.1002/jso.70292↗
  2. Artificial Intelligence-Estimated Intrapancreatic Fat and Its Relationship to Familial and Germline Pancreatic Cancer Risk. Last author DOI 10.1002/ueg2.70279↗
  3. Real world clinical characteristics of Claudin 18.2 expression in patients with pancreatic adenocarcinoma. Co-author DOI 10.1007/s00428-026-04544-9↗
  4. Socioeconomic deprivation, rurality, and travel distance negatively impact survival in early-stage pancreatic ductal adenocarcinoma but are not associated with… Last author DOI 10.1016/j.canep.2026.103124↗
  5. Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk: Balancing reassurance and vigilance. First author DOI 10.1016/j.pan.2026.08.009↗
  6. Polygenic scores for risk of pancreatic ductal adenocarcinoma: evaluation of novel and published models. Co-author DOI 10.1038/s41698-026-01479-x↗
  7. Safety and Diagnostic Performance of Pancreatic Duct Brushings for Detecting Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000002714↗
  8. Improving a Plasma Biomarker Panel for Early Detection of Pancreatic Ductal Adenocarcinoma with Aminopeptidase N (ANPEP) and Polymeric Immunoglobulin Receptor … Co-author DOI 10.1158/1078-0432.ccr-25-3297↗
  9. Pancreatic Cancer Detection Consortium Biomarker Bakeoff: A Phase II Blinded Biomarker Validation and Panel Discovery Study. Co-author DOI 10.1158/1078-0432.ccr-25-4061↗
  10. The exposome as a target for primary prevention and a tool for early detection of pancreatic cancer. Co-author DOI 10.1016/j.bpg.2025.101991↗
  11. Multimodal Pancreatic Cancer Detection Using Methylated DNA Biomarkers in Pancreatic Juice and Plasma CA 19-9: A Prospective Multicenter Study. Last author DOI 10.1016/j.cgh.2024.07.048↗
  12. Molecular Early Detection for Pancreatic Cancer in High-Risk Individuals: Are We Sure Yet? Last author DOI 10.1053/j.gastro.2025.09.033↗
  13. Genomic and Immune Landscape of Pancreatic Ductal Adenocarcinoma Associated with Germline Pathogenic Variants in ATM. Co-author DOI 10.1158/1078-0432.ccr-24-4120↗
  14. Discordant risk factors between pancreatic neuroendocrine neoplasms and pancreatic ductal adenocarcinoma. Co-author DOI 10.1530/erc-24-0142↗
  15. Identification of pancreatic cancer risk factors from clinical notes using natural language processing. Last author DOI 10.1016/j.pan.2024.03.016↗
  16. Early detection of pancreatic cancer: Study design and analytical considerations in biomarker discovery and early phase validation studies. Co-author DOI 10.1016/j.pan.2024.10.012↗
  17. Machine Learning Models for Pancreatic Cancer Risk Prediction Using Electronic Health Record Data-A Systematic Review and Assessment. Last author DOI 10.14309/ajg.0000000000002870↗
  18. Long-Term Outcomes and Risk of Pancreatic Cancer in Intraductal Papillary Mucinous Neoplasms. Last author DOI 10.1001/jamanetworkopen.2023.37799↗
  19. Risk of Syndrome-Associated Cancers Among First-Degree Relatives of Patients With Pancreatic Ductal Adenocarcinoma With Pathogenic or Likely Pathogenic Germlin… Co-author DOI 10.1001/jamaoncol.2023.0806↗
  20. Bounding box-based 3D AI model for user-guided volumetric segmentation of pancreatic ductal adenocarcinoma on standard-of-care CTs. Co-author DOI 10.1016/j.pan.2023.05.008↗
  21. Pancreatic Cancer is More Frequently Early Stage at Diagnosis in Surgically Resected Intraductal Papillary Mucinous Neoplasms With Preoperative Surveillance. Last author DOI 10.1016/j.gastha.2022.07.004↗
  22. Pancreatic cancer risk to siblings of probands in bilineal cancer settings. Co-author DOI 10.1016/j.gim.2022.01.016↗
  23. Tissue methylated DNA markers for sporadic pancreatic cancer are strongly associated with familial and genetically predisposed pancreatic cancer. Co-author DOI 10.1016/j.pan.2022.06.259↗
  24. Radiomics-based Machine-learning Models Can Detect Pancreatic Cancer on Prediagnostic Computed Tomography Scans at a Substantial Lead Time Before Clinical Diag… Co-author DOI 10.1053/j.gastro.2022.06.066↗
  25. Chronic Pancreatitis Is a Risk Factor for Pancreatic Cancer, and Incidence Increases With Duration of Disease: A Systematic Review and Meta-analysis. Last author DOI 10.14309/ctg.0000000000000463↗
  26. Determining age and sex-specific distribution of pancreatic whole-gland CT attenuation using artificial intelligence aided image segmentation: Associations wit… Last author DOI 10.1016/j.pan.2021.08.004↗
  27. Early detection of pancreatic cancer: current state and future opportunities. Last author DOI 10.1097/mog.0000000000000770↗
  28. High Detection Rates of Pancreatic Cancer Across Stages by Plasma Assay of Novel Methylated DNA Markers and CA19-9. Co-author DOI 10.1158/1078-0432.ccr-20-0235↗
  29. How I Approach Screening for Pancreatic Cancer Last author DOI 10.14309/ajg.0000000000001305↗
  30. Methylated DNA in Pancreatic Juice Distinguishes Patients With Pancreatic Cancer From Controls. Co-author DOI 10.1016/j.cgh.2019.07.017↗
  31. Corrigendum to "Peripheral blood monocyte counts are elevated in the pre-diagnostic phase of pancreatic cancer: A population based study" [Pancreatology. 19 (8… Last author DOI 10.1016/j.pan.2020.03.006↗
  32. Pancreatic ductal adenocarcinoma is associated with a unique endocrinopathy distinct from type 2 diabetes mellitus. Co-author DOI 10.1016/j.pan.2020.05.010↗
  33. Computerized tomography scan in pre-diagnostic pancreatic ductal adenocarcinoma: Stages of progression and potential benefits of early intervention: A retrospe… Co-author DOI 10.1016/j.pan.2020.07.410↗
  34. Peripheral blood monocyte counts are elevated in the pre-diagnostic phase of pancreatic cancer: A population based study. Last author DOI 10.1016/j.pan.2019.10.002↗
  35. High-Grade Dysplasia in Resected Main-Duct Intraductal Papillary Mucinous Neoplasm (MD-IPMN) is Associated with an Increased Risk of Subsequent Pancreatic Canc… Co-author DOI 10.1038/s41395-018-0403-2↗
  36. Association between HBsAg positivity and pancreatic cancer: a meta-analysis. Co-author DOI 10.1007/s12029-014-9618-7↗
  37. Hepatoid variant of pancreatic cancer: insights from a case and literature review. Co-author DOI 10.6092/1590-8577/1476↗
  38. Pancreatic cancer: an endoscopic perspective. Co-author DOI 10.1586/egh.11.93↗
  39. Catastrophic arteriovenous thromboembolism as initial manifestation of pancreatic cancer. Co-author DOI 10.6092/1590-8577/672↗

Trials 2

  1. Molecular Detection of Advanced Neoplasia in Pancreatic Cysts Principal investigator NCT03855800↗
  2. Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders Principal investigator NCT00830557↗

Grants 1

  1. Mayo Clinic Prospective Resource for Biomarker Validation and Early Detection of Pancreatic Cancer U01CA210138↗

Closest collaborators

The 25 strongest of 109 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ann L. Oberg · 7 shared papers, 2024–2026 · strength 1.73
  2. Gloria M. Petersen · 5 shared papers, 1 shared grant, 2020–2026 · strength 1.68
  3. Suresh T. Chari · 12 shared papers, 2019–2023 · strength 1.41
  4. Douglas W. Mahoney · 7 shared papers, 2020–2026 · strength 1.30
  5. Jaime de la Fuente · 8 shared papers, 2019–2025 · strength 1.30
  6. John B. Kisiel · 6 shared papers, 2020–2026 · strength 1.14
  7. Kenneth Zaret · 1 shared grant, 2026 · strength 1.00
  8. Rondell Patrell Graham · 5 shared papers, 2022–2026 · strength 0.91
  9. Santhi Swaroop Vege · 6 shared papers, 2019–2026 · strength 0.78
  10. Anup Kumar Mishra · 3 shared papers, 2024–2026 · strength 0.72
  11. Shruti Chandra · 4 shared papers, 2020–2025 · strength 0.67
  12. Naoki Takahashi · 5 shared papers, 2019–2026 · strength 0.67
  13. Kenneth S. Zaret · 3 shared papers, 2024–2026 · strength 0.67
  14. Vinay Chandrasekhara · 4 shared papers, 2021–2026 · strength 0.64
  15. Jianing Li · 1 shared paper, 2026 · strength 0.63
  16. Bradford Chong · 2 shared papers, 2024–2026 · strength 0.61
  17. Ajit Harishkumar Goenka · 4 shared papers, 2020–2026 · strength 0.61
  18. Sonal Gandhi · 3 shared papers, 2022–2025 · strength 0.60
  19. Krystal C. Mills · 2 shared papers, 2025–2026 · strength 0.59
  20. Kari G. Rabe · 3 shared papers, 2022–2025 · strength 0.58
  21. Sean Patrick Cleary · 3 shared papers, 2022–2026 · strength 0.56
  22. Ferga C. Gleeson · 5 shared papers, 2019–2025 · strength 0.56
  23. Randall K. Pearson · 4 shared papers, 2019–2026 · strength 0.55
  24. Laurens P. Janssens · 3 shared papers, 2021–2026 · strength 0.54
  25. Garima Suman · 3 shared papers, 2022–2026 · strength 0.51

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.